Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Updates on the use of gepants in migraine

Nina Yakovlevna Riggins, MD, FAAN, University of California, San Francisco, CA, gives an overview of the latest updates regarding the use of gepants for the treatment of migraine. Rimegepant was first approved for acute migraine treatment in February 2020, but in May 2021 received expanded FDA approval as a preventive migraine treatment, making it the first and only gepant that can be used in both acute a preventive settings. In March 2023, zavegepant was granted FDA approval for the treatment of acute migraine. Zavegepant is the first gepant approved for an intranasal route of administration. Furthermore, in April 2023, atogepant received expanded FDA approval as a preventive treatment for adults with chronic migraine. The recent approvals and ongoing research on gepants and other drug classes promise a bright future for the treatment of migraine. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.